Combined Therapy Can Reduce Chance of Recurrence in Women with Small, HER2+ Breast Tumors, Study Shows
Dana-Farber Cancer InstituteDana-Farber researchers report women with small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years.